

**IN THE SPECIFICATION:**

**CROSS-REFERENCE TO RELATED APPLICATIONS**

This is a National Phase Filing Under 35 U.S.C. 371, of International Application No. PCT/US05/08973, filed March 18, 2005, which claims the benefit of priority of United States Provisional Patent Application Serial No. 60/554,538, filed March 19, 2004, both of which are incorporated herein by reference.

Please replace the following paragraph at page 22, lines 26-32:

The antibody solutions with increasing concentration of 0 (PBS), 0.5, 5, 50 and 500 µg/ml ~~µg/ml~~ were spotted (spotting volume, 1 nl) on both polyacrylamide (hydrogel)- and nitrocellulose (FAST)-based antibody chips at the Michigan Life Sciences Corridor (MLSC) Proteomics facility at Van Andel Institute using split pin technology.

Please replace the following paragraph at page 31, lines 1-15:

**Table 2.** IgG concentration-dependent visible spots obtained after hybridizaion of drug metabolizing enzyme slides with secondary anti-mouse and anti-rabbit IgG.

The image of the slide is shown in Figure 1, "Quality Control". Antibodies for the array were spotted in 4 blocks (2 spots ~~spot~~ in each concentration) in top and 4 repeating blocks in bottom. Spots in block 1 (144 spots) were used for %visible spot counting.

IgG concentration (µg/ml)	%Visible Spot	<u>% Not Visible Spot</u>
500	100	<u>0</u>
50	89	<u>11</u>
5	28	<u>72</u>
0.5	0	<u>100</u>